Home › Trials › NCT06847191

Evaluating NE3107 for neurological symptoms in Long COVID patients

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults With Long COVID

Phase 2 Interventional BioVie Inc. · NCT06847191

This study is testing if a new medication called NE3107 can help adults with Long COVID feel better by reducing symptoms like brain fog and fatigue.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment208 (estimated)
Ages18 Years to 69 Years
SexAll
SponsorBioVie Inc. Industry-sponsored
Locations20 sites (Palo Alto, California and 19 other locations)
Trial IDNCT06847191 on ClinicalTrials.gov

What this trial studies

This clinical trial investigates the effects of NE3107 on neurological symptoms associated with Long COVID, such as brain fog and fatigue. Participants aged 18 to 64 who have experienced these symptoms for at least three months will be randomly assigned to receive either NE3107 or a placebo for 84 days. The study includes five clinic visits for assessments and follow-up phone calls to monitor progress and side effects. The goal is to determine if NE3107 can effectively alleviate these debilitating symptoms.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 64 diagnosed with Long COVID, experiencing fatigue and brain fog for at least three months.

Not a fit: Patients who have received a COVID-19 vaccination within 30 days or have a history of major mental or physical illness prior to COVID-19 may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from neurological symptoms of Long COVID.

How similar studies have performed: While there have been various studies on Long COVID, the specific approach of using NE3107 for neurological symptoms is novel and has not been extensively tested.

Eligibility criteria

Show full inclusion / exclusion criteria 
Key Inclusion Criteria:

* 18 years to 69 years of age
* Long COVID with neurological symptoms as defined below:

  1. Current symptoms of at least fatigue and neurocognitive impairment that began or worsened after an index SARS-CoV-2 infection that occurred at least 3 months prior to screening. Index SARS-CoV-2 infection is defined as either: 1) an episode of COVID-19 with a positive nucleic acid or antigen test during acute illness, as documented in the medical record, or 2) a documented clinical diagnosis of COVID-19, which can be based on a patient-reported positive test for COVID-19. Note that a documented diagnosis of Long COVID is not required for inclusion.
  2. Symptoms cannot be explained by any concomitant condition or diagnosis, in the opinion of the investigator.
  3. Symptom duration for at least 3 months. diagnosed with Long COVID with symptoms of fatigue and brain fog for at least 3 months
* Agree to maintain any other regular medications at current doses for the duration of the trial (except for essential need of new medication or dose change, as prescribed by a physician)
* Agree to use birth control measures
* Provide voluntary consent
* Willing to allow blood collection
* Pass all screening tests and procedures

Key Exclusion Criteria:

* Has received a COVID-19 vaccination within 14 days
* Previous admission to the intensive care unit for COVID-19
* Medical history of major mental or physical illness prior to COVID-19 infection

Where this trial is running

Palo Alto, California and 19 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Long COVIDCOVID-19NeurocognitionFatiguePost-exertional malaiseSleepSARS-CoV-2Brain fog
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.